SAB Biotherapeutics Statistics
Share Statistics
SAB Biotherapeutics has 9.29M
shares outstanding. The number of shares has increased by -99.14%
in one year.
| Shares Outstanding | 9.29M |
| Shares Change (YoY) | -99.14% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.5% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.89% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.03 and the forward
PE ratio is null.
SAB Biotherapeutics's PEG ratio is
0.02.
| PE Ratio | -1.03 |
| Forward PE | n/a |
| PS Ratio | 26.54 |
| Forward PS | 0.3 |
| PB Ratio | 1.35 |
| P/FCF Ratio | -1.01 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.98,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.98 |
| Quick Ratio | 2.98 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.16 |
| Debt / FCF | -0.13 |
| Interest Coverage | -134.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $20,990.63 |
| Profits Per Employee | $-541,354.11 |
| Employee Count | 63 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -0.99% in the
last 52 weeks. The beta is 0.48, so SAB Biotherapeutics's
price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -0.99% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 50.37 |
| Average Volume (20 Days) | 22,365 |
Income Statement
In the last 12 months, SAB Biotherapeutics had revenue of 1.32M
and earned -34.11M
in profits. Earnings per share was -3.68.
| Revenue | 1.32M |
| Gross Profit | -3.47M |
| Operating Income | -42.91M |
| Net Income | -34.11M |
| EBITDA | -28.99M |
| EBIT | -33.79M |
| Earnings Per Share (EPS) | -3.68 |
Full Income StatementBalance Sheet
The company has 8.9M in cash and 4.67M in
debt, giving a net cash position of 4.23M.
| Cash & Cash Equivalents | 8.9M |
| Total Debt | 4.67M |
| Net Cash | 4.23M |
| Retained Earnings | -124.17M |
| Total Assets | 44.2M |
| Working Capital | 15.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -34.29M
and capital expenditures -337.26K, giving a free cash flow of -34.63M.
| Operating Cash Flow | -34.29M |
| Capital Expenditures | -337.26K |
| Free Cash Flow | -34.63M |
| FCF Per Share | -3.74 |
Full Cash Flow StatementMargins
Gross margin is -262.41%, with operating and profit margins of -3244.87% and -2579.03%.
| Gross Margin | -262.41% |
| Operating Margin | -3244.87% |
| Pretax Margin | -2579.03% |
| Profit Margin | -2579.03% |
| EBITDA Margin | -2192.54% |
| EBIT Margin | -3244.87% |
| FCF Margin | -2618.65% |
